Although it is currently unclear whether CD11c+ABCs can be depleted by anti-CD20 or anti-CD19 therapies, targeting CD11c+ABCs is an appealing approach for the treatment of patients with autoimmune diseases. This evidence concerns the gene ITGAX and autoimmune disease.